Table 1.

Demographic and clinical characteristics at baseline

Characteristic	Value
Age, years	43.2 (10.4)
Female	229 (71%)
Years since diagnosis of MS	7.2 (7.3)
Median (range)	5 (0.5–12)
Frequency of relapses in past 2 years
0	135 (41.5%)
1	119 (36.6%)
≥ 2	72 (21.8%)
Mean number of relapses (excluding zero)	1.5 (0.7)
Median (range), excluding zero	1 (1–2)
Baseline ARR (95%CI)	0.42 (0.38–0.48)
EDSS
Mean (SD)	1.75 (1.5)
Median (range)	1.5 (1–2.5)
Patients with gadolinium-enhancing lesions*	94 (30.1%)
Mean number of gadolinium-enhancing lesions	2.1 (1.8)
Patients who switched DMT	208 (64%)
Mean number of previous DMTs	1.5 (0.9)
Last DMT before teriflunomide administration
Interferons	106 (51%)
Glatiramer acetate	51 (24.5%)
Dimethyl fumarate	27 (13%)
Immunosuppressants†	8 (5.3%)

Data are shown as mean (SD) or number (%) unless otherwise stated. *MRI was available in 312 patients. ^†Fingolimod (n = 5), azathioprine (n = 2) and natalizumab (n = 1)

CI confidence interval, DMT disease-modifying therapy, EDSS Expanded Disability Status Scale, Gd+ gadolinium, MRI magnetic resonance imaging, SD standard deviation